


CLAIMS

1. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and:

- 5 (a) an inhibitor of the RSV fusion protein; and  
 (b) a benzodiazepine derivative capable of inhibiting RSV replication.

2. A composition according to claim 1, wherein component (b) is a compound of formula (V), or a pharmaceutically acceptable salt thereof,



wherein:

- $R^1$  represents  $C_{1-6}$  alkyl, aryl or heteroaryl;
- $R^2$  represents hydrogen or  $C_{1-6}$  alkyl;
- 15 - each  $R^3$  is the same or different and represents halogen, hydroxy,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  haloalkoxy, amino, mono( $C_{1-6}$  alkyl)amino, di( $C_{1-6}$  alkyl)amino, nitro, cyano,  $-CO_2R'$ ,  $-CONR'R''$ ,  $-NH-CO-R'$ ,  $-S(O)R'$ ,  $-S(O)_2R'$ ,  $-NH-S(O)_2R'$ ,  $-S(O)NR'R''$  or  $-S(O)_2NR'R''$ , wherein each  $R'$  and  $R''$  is the same or different and represents hydrogen or  $C_{1-6}$  alkyl;
- 20 - n is from 0 to 3;
- $R^4$  represents hydrogen or  $C_{1-6}$  alkyl;
- $R^5$  represents  $C_{1-6}$  alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-6}$  alkyl)-, heteroaryl-( $C_{1-6}$  alkyl)-, carbocyclyl-( $C_{1-6}$  alkyl)-, heterocyclyl-( $C_{1-6}$  alkyl)-, aryl-( $C_{1-6}$  hydroxyalkyl)-, heteroaryl-( $C_{1-6}$  hydroxyalkyl)-, carbocyclyl-( $C_{1-6}$  hydroxyalkyl)-, heterocyclyl-( $C_{1-6}$  hydroxyalkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or  $-XR^6$ ;
- 25

- X represents -CO-, -S(O)- or -S(O)<sub>2</sub>-; and
  - R<sup>6</sup> represents C<sub>1-6</sub> alkyl, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)-, aryl-(C<sub>1-6</sub> alkyl)-O-, heteroaryl-(C<sub>1-6</sub> alkyl)-O-, carbocyclyl-(C<sub>1-6</sub> alkyl)-O-, heterocyclyl-(C<sub>1-6</sub> alkyl)-O- or -NR'<sup>5</sup>R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-6</sub> alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)- or heterocyclyl-(C<sub>1-6</sub> alkyl)-.
- 10 3. A composition according to claim 2 wherein:
- each R<sup>3</sup> is the same or different and represents halogen, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> haloalkoxy, amino, mono(C<sub>1-6</sub> alkyl)amino, di(C<sub>1-6</sub> alkyl)amino, nitro, cyano, -CO<sub>2</sub>R', -CONR'<sup>10</sup>R'', -NH-CO-R', -S(O)R', -S(O)<sub>2</sub>R', -NH-S(O)<sub>2</sub>R' or -S(O)NR'<sup>10</sup>R'', wherein each R' and R'' is the same or different and represents hydrogen or C<sub>1-6</sub> alkyl;
  - R<sup>5</sup> represents C<sub>1-6</sub> alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)- or -XR<sup>6</sup>;
  - X represents -CO-, -S(O)- or -S(O)<sub>2</sub>-; and
  - R<sup>6</sup> represents C<sub>1-6</sub> alkyl, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C<sub>1-6</sub> alkyl)-, heteroaryl-(C<sub>1-6</sub> alkyl)-, carbocyclyl-(C<sub>1-6</sub> alkyl)-, heterocyclyl-(C<sub>1-6</sub> alkyl)- or -NR'<sup>20</sup>R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-6</sub> alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C<sub>1-6</sub> alkyl)- or heteroaryl-(C<sub>1-6</sub> alkyl)-.
- 25 4. A composition according to either claim 2 or claim 3, wherein R<sup>1</sup> is C<sub>1-2</sub> alkyl or aryl.
5. A composition according to any one of claims 2 to 4 wherein R<sup>2</sup> is hydrogen.
6. A composition according to any one of claims 2 to 5 wherein R<sup>3</sup> is halogen,
- 30 hydroxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkoxy, amino, mono(C<sub>1-4</sub> alkyl)amino or di(C<sub>1-4</sub> alkyl)amino.

7. A composition according to claim 6, wherein  $R^3$  is fluorine, chlorine, bromine,  $C_{1-2}$  alkyl,  $C_{1-2}$  alkoxy,  $C_{1-2}$  alkylthio,  $C_{1-2}$  haloalkyl,  $C_{1-2}$  haloalkoxy, amino, mono( $C_{1-2}$  alkyl)amino or di ( $C_{1-2}$  alkyl)amino.

5

8. A composition according to any one of claims 2 to 7 wherein  $R^4$  is hydrogen or  $C_{1-2}$  alkyl.

9. A composition according to any one of claims 2 to 8 wherein  $R^5$  is  $C_{1-6}$  alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-4}$  alkyl)-, heteroaryl-( $C_{1-4}$  alkyl)-, carbocyclyl-( $C_{1-4}$  alkyl)-, heterocyclyl-( $C_{1-4}$  alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or - $XR^6$ .

10. A composition according to claim 9, wherein  $R^5$  is  $C_{1-4}$  alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl-( $C_{1-2}$  alkyl)-, heteroaryl-( $C_{1-2}$  alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or - $XR^6$ .

11. A composition according to claim 10, wherein  $R^5$  is  $C_{1-4}$  alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl- $CH_2$ -, furanyl- $CH_2$ -, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or - $XR^6$ .

12. A composition according to any one of claims 2 to 11 wherein X is -CO- or -S(O)<sub>2</sub>-.

13. A composition according to any one of claims 2 to 12 wherein, when  $R^6$  is a group  $NR'R''$  wherein each  $R'$  and  $R''$  is the same or different and represents hydrogen,  $C_{1-4}$  alkyl, aryl, carbocyclyl, heterocyclyl, aryl-( $C_{1-4}$  alkyl)- or heteroaryl-( $C_{1-4}$  alkyl)-.

14. A composition according to claim 13, wherein when  $R^6$  is a group - $NR'R''$  each  $R'$  and  $R''$  is the same or different and represents hydrogen,  $C_{1-4}$  alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl- $CH_2$ -.


15. A composition according to claim 14, wherein when  $R^6$  is a group  $-NR'R''$  and one of  $R'$  and  $R''$  is hydrogen.

16. A composition according to any one of claims 2 to 15 wherein  $R^6$  is  $C_{1-6}$  alkyl, hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl- $(C_{1-4}$  alkyl)-, heteroaryl- $(C_{1-4}$  alkyl)-, carbocyclyl- $(C_{1-4}$  alkyl)-, heterocyclyl- $(C_{1-4}$  alkyl)-, aryl- $(C_{1-4}$  hydroxyalkyl)-, heteroaryl- $(C_{1-4}$  hydroxyalkyl)-, carbocyclyl- $(C_{1-4}$  hydroxyalkyl)-, heterocyclyl- $(C_{1-4}$  hydroxyalkyl)-, aryl- $(C_{1-4}$  alkyl)-O-, heteroaryl- $(C_{1-4}$  alkyl)-O-, carbocyclyl- $(C_{1-4}$  alkyl)-O-, heterocyclyl- $(C_{1-4}$  alkyl)-O- or  $-NR'R''$ .

17. A composition according to claim 16, wherein  $R^6$  is  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl- $(C_{1-2}$  alkyl)-, phenyl- $(C_{1-2}$  alkyl)-O-, heteroaryl- $(C_{1-2}$  alkyl)-, phenyl- $(C_{1-2}$  hydroxyalkyl)-, heteroaryl- $(C_{1-2}$  hydroxyalkyl)- or  $-NR'R''$ .

18. A composition according to claim 17, wherein  $R^6$  is  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl- $(C_{1-2}$  alkyl)-, phenyl- $CH_2-CH(OH)-$ , phenyl- $CH(OH)-CH_2-$ , phenyl- $(C_{1-2}$  alkyl)-O-, 1H-benzo[d]imidazol-2(3H)-onyl or  $-NR'R''$ .

19. A composition according to any one of the claims 2 to 18 wherein the benzodiazepine derivative of formula (V) is a benzodiazepine derivative of formula (Va):



wherein:

- $R^1$  is phenyl or methyl;
- $R^3$  is methyl or chlorine;
- $n$  is 0 or 1;
- $R^4$  is hydrogen or methyl;
- 5 -  $R^5$  is phenyl-CH<sub>2</sub>-, furanyl-CH<sub>2</sub>-, thienyl-C(O)-C(O)- or -XR<sup>6</sup>;
- $X$  is -CO- or -S(O)<sub>2</sub>-; and
- $R^6$  is C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C<sub>1-2</sub> alkyl)-, phenyl-CH<sub>2</sub>-CH(OH)-phenyl-CH(OH)-CH<sub>2</sub>-, phenyl-(C<sub>1-2</sub> alkyl)-O-, 1H-benzo[d]imidazol-2(3H)-onyl or -NR'<sup>6</sup>R'' wherein each R' and R'' is the same or different and represents hydrogen, C<sub>1-4</sub> alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH<sub>2</sub>)-, the phenyl moiety in the group  $R^1$  being unsubstituted or substituted by a single fluorine, chlorine, C<sub>1-2</sub> alkyl, C<sub>1-2</sub> alkoxy, C<sub>1-2</sub> alkylthio, C<sub>1-2</sub> haloalkyl or C<sub>1-2</sub> haloalkoxy substituent;

the aryl moieties in the groups  $R^5$  and  $R^6$  being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, C<sub>1-4</sub> alkyl, C<sub>2-4</sub> acyl, hydroxy, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkoxy, amino, mono(C<sub>1-4</sub> alkyl)amino, di(C<sub>1-4</sub> alkyl)amino, nitro, -CO<sub>2</sub>R', -S(O)<sub>2</sub>R' and -S(O)<sub>2</sub>NH<sub>2</sub>, wherein R' represents C<sub>1-2</sub> alkyl;

the heteroaryl moieties in the groups  $R^5$  and  $R^6$  being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C<sub>1-2</sub> alkyl, C<sub>1-2</sub> haloalkyl and di(C<sub>1-2</sub> alkyl)amino; and

the heterocyclyl and carbocyclyl moieties in the  $R^6$  group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> haloalkyl and nitro.

20. A composition according to claim 1, wherein the benzodiazepine derivative of formula (V) is:

30 Cyclohexanecarboxylic acid 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

3-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

4-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

5        2-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-trifluoromethylbenzamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

10        Thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-amide;

Furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

15        Piperidine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

Morpholine-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

4-Nitro- N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

3-Nitro- N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

20        4-Methyl-piperazine-1-carboxylic acid -(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

3,4-Dichloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

25        N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-trifluoromethylbenzamide;

4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

30        2-Chloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;  
2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
benzamide;

(S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]  
5 diazepin-3-yl)-benzamide

Benzo[b]thiophene-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e]  
[1,4]diazepin-3-yl)-amide;

2,3-Dihydro-benzofuran-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)-amide;

10 Isoxazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]  
diazepin-3-yl)-amide;

Benzo[b]thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e]  
[1,4]diazepin-3-yl)-amide;

Thiophen-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]  
15 diazepin-3-yl)-amide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isonicotinamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
methanesulfonamide;

20 Propane-1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)-amide;

Butane-1-sulfonic acid--(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)-amide;

2-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
25 benzenesulfonamide;

3-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
benzenesulfonamide;

4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
benzenesulfonamide;

30 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
benzenesulfonamide;

- 3-(2-Nitro-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;  
3-(3-Nitro-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;  
3-(4-Nitro-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;  
3-(2-Methoxy-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;  
5 3-(3-Methoxy-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;  
5-Phenyl-3-(2-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][1,4]diazepin-2-one;  
one;  
5-Phenyl-3-(3-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][1,4]diazepin-2-one;  
one;  
10 5-Phenyl-3-(4-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][1,4]diazepin-2-one;  
one;  
3-[(Furan-2-ylmethyl)-amino]-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;  
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;  
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
15 isobutyramide;  
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-methanesulfonamide;  
Furan-2-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;  
20 Thiophene-2-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;  
Cyclohexanecarboxylic acid (7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;  
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-methoxy-benzamide;  
25 methoxy-benzamide;  
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-methoxy-benzamide;  
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-nitro-benzamide;  
30 2-(2-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;



2-(3-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]  
diazepin-3-yl)-acetamide;

2-(4-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]  
diazepin-3-yl)-acetamide;

5 2-(4-Nitro-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
acetamide;

2-(3-Nitro-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
acetamide;

10 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(2-  
trifluoromethyl-phenyl)-acetamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(3-  
trifluoromethyl-phenyl)-acetamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(4-  
trifluoromethyl-phenyl)-acetamide;

15 1-(2-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]  
diazepin-3-yl)-urea;

1-(2-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
urea;

20 1-(2-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
urea;

1-(4-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
urea;

1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-p-tolyl-urea;

25 1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
urea;

1-(4-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
urea;

(S)-1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]  
diazepin-3-yl)-urea;

30 4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e]  
[1,4]diazepin-3-yl)-benzamide;

(S)- 4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

5 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(S)- 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

10 (S)- 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-trifluoromethyl-benzamide;

2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

15 (S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Hydroxy- N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

20 (S)-2-Hydroxy- N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

1H-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-1H-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

25 3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

30 N-[7-Chloro-5-(2-fluoro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepine-3-yl]-4-methoxy-benzamide;

1-(2-Fluoro-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
urea;

1-(4-Methoxy-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]  
diazepin-3-yl)-urea;

5 1-(3-Methyl-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
urea;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethyl-  
phenyl)-urea;

10 4-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)-benzamide;

4-Methoxy-3-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)benzamide;

3-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
benzamide;

15 5-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)benzamide;

5-Fluoro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
benzamide;

20 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
benzamide;

5-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
benzamide;

3-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-  
benzamide;

25 3-(2-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]  
diazepin-3-yl)propionamide;

3-(3-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]  
diazepin-3-yl)-propionamide;

30 3-(4-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]  
diazepin-3-yl)-propionamide;

N-[5-(3-Chloro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-methoxy-benzamide;

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-methoxy-benzamide;

5 N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-nitro-benzamide;

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitro-benzamide;

10 4-Methoxy-N-[2-oxo-5-(4-trifluoromethyl-phenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-benzamide;

2-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-benzamide;

4-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-benzamide;

15 2-Ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2,4-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

20 2-Bromo-5-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Methoxy-N-[5-(3-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-benzamide

N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitro-benzamide;

25 2-Methoxy-N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

30 2-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid benzyl ester;

1-(3,5-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

5 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethoxy-phenyl)-urea;

1-(4-Bromo-2-trifluoromethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

10 1-(4-Bromo-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2,3-Dichloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2,6-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

15 1-(2-Chloro-6-methyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

20 1-(2-Methylsulfanyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(2,6-Dichloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

5-tert-Butyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

25 2,5-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

1-(2,6-Difluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

30 1-(3-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(3-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]

diazepin-3-yl)-urea;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(3-trifluoromethyl-phenyl)-urea;

5 1-(3-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

2-Methoxy-4-methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

4-Methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

10 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamic acid methyl ester;

2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

2,6-Difluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

15 N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-propoxy-benzamide;

2-Iodo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-terephthalamic acid methyl ester;

20 4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-m-tolyl-urea;

2-Methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

25 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-sulfamoyl-benzamide;

2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-propionamide

30 3-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-propionamide ;

3-(2-Fluoro-phenyl)-1-methyl-1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]

diazepin-3-yl)-urea;

2-Methoxy-N-methyl-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]

diazepin-3-yl)-benzamide;

1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

5 1-Cycloheptyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

4,5-Dimethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide;

10 Piperidine-1-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide;

15 N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-isobutyramide;

Furan-2-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Thiophene-2-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

20 Cyclohexanecarboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Piperidine-1-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

25 N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isonicotinamide;

5-Methyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

Pyrazine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

30 N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-isobutyramide;

Thiophene-2-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Cyclohexanecarboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

5 Piperidine-1-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Piperidine-4-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

10 Cyclohexanecarboxylic acid (8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

Thiophene-2-carboxylic acid (8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-thiophene-2-yl-urea;

15 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-thiophene-3-yl-urea;

Pyridine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

20 1H-Pyrazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

2-Ethoxy-naphthalene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

25 9-Oxo-9H-fluorene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

2-Oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

30 (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl ester;



(S)-4,5-Dibromo-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(S)-Benzofuran-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

5 (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid methyl ester;

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid ethyl ester;


(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid isobutyl ester; and

10 2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-thiophene-2-yl-acetamide.

21. A composition according to any one of claims 2 to 20, wherein the benzodiazepine derivative of formula (V) is 1-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea, 2-methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide or 4-methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide.


22. A composition according to claim 21, wherein the benzodiazepine derivative of formula (V) is 1-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

23. A composition according to any one of the preceding claims wherein component (a) is a compound of formula (I), or a pharmaceutically acceptable salt thereof,



wherein:

- X is a direct link or C<sub>1-6</sub> alkyl; said C<sub>1-6</sub> alkyl being optionally substituted with halogen, oxo, cyano, hydroxyl, OCOR<sub>4</sub> or S(O)<sub>n</sub>-C<sub>1-6</sub> alkyl;
- Y is R<sub>4</sub>, NR<sub>4</sub>R<sub>5</sub>, NCOR<sub>4</sub>, =N-OR<sub>4</sub>, -CONHR<sub>4</sub>, COOR<sub>4</sub>, -OR<sub>4</sub>, aryl, heteroaryl, cyclyl or heterocyclyl, where R<sub>4</sub> and R<sub>5</sub> are H or C<sub>1-6</sub> alkyl;
- Z is CR<sub>6</sub>R<sub>7</sub>, where R<sub>6</sub> and R<sub>7</sub> are independently H, or straight, branched or cyclic C<sub>1-6</sub> alkyl;
- n is 1-2;
- R<sub>1</sub> is CONR<sub>4</sub>R<sub>5</sub>, CO<sub>2</sub>R<sub>4</sub> or C<sub>1-6</sub> alkyl, said C<sub>1-6</sub> alkyl can be optionally substituted with OR<sub>4</sub> or NR<sub>8</sub>R<sub>9</sub>;
- R<sub>8</sub> and R<sub>9</sub> are each independently H, C<sub>1-6</sub> alkyl, SO<sub>2</sub>R<sub>5</sub>, CO<sub>2</sub>R<sub>4</sub> or COR<sub>4</sub>;
- R<sub>2</sub> is selected from the group consisting of NH<sub>2</sub>, CONR<sub>6</sub>R<sub>7</sub>, heteroaryl, C<sub>2-6</sub> alkenyl, CO<sub>2</sub>R<sub>4</sub>, N=CPh<sub>2</sub>, C(=NH)NH<sub>2</sub> and C<sub>1-6</sub> alkyl; said alkyl optionally substituted with a member selected from the group consisting of halogen, CN, NR<sub>10</sub>R<sub>11</sub>, OSO<sub>2</sub>R<sub>4</sub> and OR<sub>4</sub>;
- R<sub>10</sub> and R<sub>11</sub> are each independently selected from the group consisting of H, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, CO<sub>2</sub>R<sub>4</sub>, COR<sub>4</sub> and SO<sub>2</sub>R<sub>4</sub>;
- R<sub>3</sub> is selected from the group consisting of (1) CO<sub>2</sub>R<sub>9</sub>; (2) C<sub>1-6</sub> alkyl optionally substituted with CN, OR<sub>4</sub> or NR<sub>6</sub>R<sub>7</sub>; and (3) C<sub>2-6</sub> alkenyl substituted with CN;
- Q is a member selected from the group consisting of




A is C or N, optionally substituted with H, halogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, cyano-C<sub>1-6</sub> alkyl, CO<sub>2</sub>R<sub>4</sub>, aryl, benzoaminocarbonyl, hydroxybenzyl, SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub> or C<sub>3-6</sub> cycloalkyl.

5 Where A is carbon, it may also be optionally substituted by O or S via a double bond;


B is C or N; where B is C it may be optionally substituted by H, C<sub>1-6</sub> alkyl, NO<sub>2</sub>, CN, halogen, COR<sub>4</sub>, COOR<sub>4</sub>, CONHR<sub>4</sub>C(=NH)NH<sub>2</sub> or C(=NOH)NH<sub>2</sub>.

24. A composition according to any of claims 1 to 22, wherein component (a) is a  
 10 compound of the formula (I), as defined above or a pharmaceutically acceptable salt thereof, wherein at least two of R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are hydrogen, and the other is hydrogen or -C(NH)-NH<sub>2</sub> and/or either -X-Y is H, or X is a C<sub>1</sub>-C<sub>6</sub> alkylene group which is unsubstituted or substituted by a hydroxy group and Y is H, OH, CN, -NR'<sup>1</sup>R''<sup>1</sup>, -COR'<sup>1</sup>, -SO<sub>2</sub>R'<sup>1</sup> or phenyl, wherein R'<sup>1</sup> and R''<sup>1</sup> are the same or different and represent a C<sub>1</sub>-C<sub>4</sub> alkyl group and/or Z is -  
 15 CH<sub>2</sub>- and/or Q is a moiety



20 wherein B is -CH- or -N-, A<sub>1</sub> is -C(O)- or -NH- and A<sub>2</sub> is -CH<sub>2</sub>-, -CHR'<sup>1</sup>- or -NR''<sup>1</sup>-, wherein R'<sup>1</sup> is a halogen atom and R''<sup>1</sup> represents a hydrogen atom or a C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl), -SO<sub>2</sub>-N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub> or -(CO-NH)<sub>a</sub>-(C<sub>1</sub>-C<sub>4</sub> alkyl)-phenyl group, wherein a is 0 or 1, which group is unsubstituted or is substituted with a hydroxy or cyano substituent.

25. A composition according to any of claims 1 to 22, wherein component (a) is a compound of the formula (II), or a pharmaceutically acceptable salt thereof



wherein:

- 5 -  $L_1$  is  $-\text{CH}_2-$  or  $-\text{CHR}_2-\text{CO}-$
- each X is the same or different and is CH or N;
- each  $R_1$  is the same or different and is  $\text{C}_{1-6}$  alkyl, halogen, hydroxy, phenyl or  $(\text{CH}_2)_m=\text{NH}_2$ ;
- n is 1 or 2;
- 10 -  $R_2$  is  $\text{C}_{1-6}$  alkoxy or  $\text{C}_{1-6}$ alkoxy-phenyl;
- $R_3$  is  $\text{C}_{1-6}$ alkyl;
- $L_2$  is  $-\text{CH}_2-$  or  $-\text{NH}-$ ;
- Y is  $\text{C}_{1-6}$  alkyl or  $\text{C}_{1-6}$  alkenyl;
- Z is H,  $\text{N}(\text{R}_4)_2$ -,  $-\text{C}(=\text{O})-\text{R}_5$ -,  $-\text{C}(=\text{CH}_2)-\text{R}_5$ -,  $-\text{CH}(\text{OH})-\text{R}_5$ -,  $-\text{CH}(\text{CH}_3)-\text{R}_5$ -,  $-\text{CH}(\text{OCH}_3)-$
- 15  $\text{R}_5$ ;
- each  $R_4$  is the same or different and is H,  $\text{C}_{1-6}$  alkyl.
- $R_5$  is  $\text{C}_{1-6}$  alkyl-carbonyl, amino, hydroxyl, aryl, heteroaryl, carbocyclyl, heterocyclyl;
- and
- $m=1-6$

20

26. A composition according to anyone of claims 1 to 22, wherein component (a) is:

1-Cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one

{2-[2-(1,2-Dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]ethyl}-diethyl-amine

{2-[2-(3-Iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]-ethyl}-dimethyl-amine

5 1-Isopropenyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-(4-Hydroxy-benzyl)-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

10 1-Isopropenyl-3-[1-(3-oxo-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Ethyl-3-[1-(2-hydroxy-2-phenyl-ethyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

1-Ethyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

15 7-[2-(3-Isopropenyl-2-oxo-2,3-dihydrobenzoimidazol-1-ylmethyl)-benzoimidazol-1-yl]-heptanenitril

5-{3-[1-(3-Methanesulfonyl-propyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-yl}-pentanenitrile

20 3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-carboxylic acid benzylamide

1-Methanesulfonyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one

3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-sulfonic acid dimethylamide

25 1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one

Bis(5-amidino-2-benzimidazolyl)-methane

2-{2-[1-[1-(2-Amino-ethyl)-piperidin-4-ylamino]-4-methyl-benzoimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol

30 or a pharmaceutically acceptable salt thereof.

27. A composition according to any one of claims 1 to 22, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one, {2-[2-(1,2-dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]ethyl}-diethyl-amine, {2-[2-(3-iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]-ethyl}-dimethyl-amine or a pharmaceutically acceptable salt thereof.

28. A composition according to any one of claims 1 to 22, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one or 1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one or a pharmaceutically acceptable salt thereof.

29. A composition according to any one of the preceding claims wherein component (a) is present in an amount of from 0.025 wt% to 10 wt%.

30. A composition according to any one of the preceding claims wherein component (b) is present in an amount of 0.025 wt% to 10 wt%.

31. A composition according to any one of the preceding claims, for use in the treatment of the human or animal body.

32. Use of:

(a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28; and

(b) a benzodiazepine derivative defined in any one of claims 1 to 22,

in the manufacture of a medicament for use in treating or preventing an RSV infection.

33. Use according to claim 31, wherein the medicament is a composition as defined in claim 29 or 30.

34. A product comprising:

(a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28; and

(b) a benzodiazepine derivative as defined in any one of claims 1 to 22;

for separate, simultaneous or sequential use in the treatment of the human or animal body.

5

35. A product according to claim 34 for separate, simultaneous or sequential use in treating or preventing an RSV infection.

36. A method of treating or preventing an RSV infection in a patient, which method

10 comprises the administration to said patient of:

(a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28; and

(b) a benzodiazepine derivative as defined in any one of claims 1 to 22.

15 37. Use of an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with a benzodiazepine derivative as defined in any one of claims 1 to 22.

20 38. Use of a benzodiazepine derivative as defined in any one of claims 1 to 22, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28.